COMMONS

Tamiflu recall

Inquiry status: inquiry launched

The Committee reported on Tamiflu in January this year, drawing attention to the lack of transparency over the results of clinical trials of the antiviral medicine, stockpiled for use in an influenza epidemic.  The Committee concluded that the failure of manufacturers to share the full results of clinical trials with doctors, researchers and clinicians, undermines their ability to make informed decisions about treatments and the use of medicines by the NHS. The Government’s response disagreed with a number of the Committee’s recommendations, including around the availability of full methods and results of clinical trials. This inquiry will examine these issues with the Department, in addition to exploring the Cochrane Collaboration’s updated review of Tamiflu and the ramifications that access to clinical trial data has for the whole of medicine.

Further information

What's on

Date Business

No business announced

Publications

  • Close

    Glossary

    • Reports and associated evidence – Reports of Committee inquires. This category may also include Special Reports where they are used by a Committee to bring matters relating to conduct of its business to the notice of the House.
    • Responses to Reports - Responses may be published as a Special Report, or as a Command Paper. They may also be appended to a Report should the Committee have substantial comments on the Response, in which case they can be found listed under Reports. 
    • Other oral and written evidence - Evidence taken by the Committee that has yet to or did not result in the publication of a Report. This includes transcripts of recent meetings.
    • Estimate Memoranda - An Estimate memorandum is an explanatory note that accompanies a government department’s estimate (a means by which a department seeks authority from Parliament for its spending plans).
    • Correspondence - Correspondence sent from or received by the Committee or its Chair.
  • Tamiflu Recall | PDF version (PDF200 KB) HC 677 | Published 28 Oct 2014

    Evidence given by Professor Dame Sally Davies DBE FRS, Chief Medical Officer, Department of Health; Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence; Richard Douglas, Director General of Finance and NHS, Department of Health; Dr Fiona Godlee, Editor-in-Chief, British Medical Journal; Professor Carl Heneghan MRCGP, Director, Centre for Evidence-Based Medicine, University of Oxford; and Dr Ian Hudson, Chief Executive, Medicines and Healthcare Products Regulatory Agency.

  • Tamiflu Recall | PDF version (PDF200 KB) HC 677 | Published 21 Oct 2014

    Evidence given by Professor Dame Sally Davies DBE FRS, Chief Medical Officer, Department of Health; Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence; Richard Douglas, Director General of Finance and NHS, Department of Health; Dr Fiona Godlee, Editor-in-Chief, British Medical Journal; Professor Carl Heneghan MRCGP, Director, Centre for Evidence-Based Medicine, University of Oxford; and Dr Ian Hudson, Chief Executive, Medicines and Healthcare Products Regulatory Agency, gave evidence.